Insider Selling: Twist Bioscience (NASDAQ:TWST) SVP Sells 892 Shares of Stock

Key Points

• Paula Green, Senior Vice President at Twist Bioscience, sold 892 shares of stock for approximately $22,978, reducing her position by 0.71% and leaving her with about 124,837 shares valued at around $3.22 million.
• Twist Bioscience’s stock opened at $25.09 with a 12-month trading range between $24.28 and $55.33, and the company has a market cap of $1.51 billion.
• Analysts have given Twist Bioscience a "Moderate Buy" rating on average, with a target price of $49.40, reflecting positive market sentiment towards the company's future prospects.

Twist Bioscience Corporation (NASDAQ:TWST - Get Free Report) SVP Paula Green sold 892 shares of Twist Bioscience stock in a transaction that occurred on Monday, September 8th. The stock was sold at an average price of $25.76, for a total transaction of $22,977.92. Following the transaction, the senior vice president directly owned 124,837 shares in the company, valued at approximately $3,215,801.12. This represents a 0.71% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.

Paula Green also recently made the following trade(s):

• On Friday, June 20th, Paula Green sold 292 shares of Twist Bioscience stock. The stock was sold at an average price of $35.76, for a total transaction of $10,441.92.

Twist Bioscience Stock Performance

Shares of Twist Bioscience stock traded up $0.31 during mid-day trading on Monday, hitting $25.62. 814,952 shares of the stock were exchanged, compared to its average volume of 1,211,592. Twist Bioscience Corporation has a 12 month low of $24.07 and a 12 month high of $55.33. The company has a 50-day simple moving average of $30.52 and a 200 day simple moving average of $34.18. The company has a debt-to-equity ratio of 0.03, a quick ratio of 3.60 and a current ratio of 3.90. The company has a market capitalization of $1.55 billion, a P/E ratio of -17.67 and a beta of 2.31.

Twist Bioscience (NASDAQ:TWST - Get Free Report) last posted its earnings results on Monday, August 4th. The company reported ($0.47) EPS for the quarter, topping the consensus estimate of ($0.54) by $0.07. Twist Bioscience had a negative net margin of 23.51% and a negative return on equity of 29.03%. The firm had revenue of $96.06 million for the quarter, compared to analysts' expectations of $95.52 million. Twist Bioscience has set its FY 2025 guidance at EPS. Q4 2025 guidance at EPS. Sell-side analysts anticipate that Twist Bioscience Corporation will post -2.12 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of research analysts recently weighed in on TWST shares. Evercore ISI set a $46.00 price objective on shares of Twist Bioscience in a research note on Monday, August 4th. Cowen reiterated a "buy" rating on shares of Twist Bioscience in a research note on Monday, August 4th. Nine equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company's stock. According to MarketBeat, the stock currently has an average rating of "Moderate Buy" and an average target price of $49.40.

Institutional Trading of Twist Bioscience

Several hedge funds have recently added to or reduced their stakes in TWST. Versant Capital Management Inc raised its stake in shares of Twist Bioscience by 547.2% during the first quarter. Versant Capital Management Inc now owns 686 shares of the company's stock valued at $27,000 after acquiring an additional 580 shares during the last quarter. GAMMA Investing LLC raised its stake in shares of Twist Bioscience by 68.1% during the first quarter. GAMMA Investing LLC now owns 748 shares of the company's stock valued at $29,000 after acquiring an additional 303 shares during the last quarter. GF Fund Management CO. LTD. bought a new position in shares of Twist Bioscience during the fourth quarter valued at about $58,000. Mirae Asset Global Investments Co. Ltd. raised its stake in shares of Twist Bioscience by 15.0% during the second quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,315 shares of the company's stock valued at $85,000 after acquiring an additional 302 shares during the last quarter. Finally, Geneos Wealth Management Inc. bought a new position in shares of Twist Bioscience during the second quarter valued at about $97,000.

Twist Bioscience Company Profile

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.